We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It's of no surprise to me that our P3 is underway in France. It will be ongoing in many countries by now!
https://video.lefigaro.fr/figaro/video/interferons-anticorps-monoclonaux-olivier-veran-fait-le-point-sur-les-traitements-contre-le-covid-19/
The original Le Figaro video from the press conference for those confident in French
Is this post from 1855 naming sng 001 not correct then ?
Synairgen Research Ltd
Aurore.Moreau@p arexel.com; Estelle.Besson@pa rexel.com; Christelle.DeBortoli @parexel.com
Essai de phase III, randomisé, en double aveugle, contrôlé par placebo, visant à déterminer l’efficacité et la sécurité d’emploi du SNG001
inhalé pour le traitement des patients hospitalisés pour une forme modérée de la maladie à coronavirus 2019 (COVID-19)
Joey holey guacamole. Thinking.... need to digest this....
https://twitter.com/MARYau_MCU_PH/status/1365023515146076164
The French Dr Aurelien Mary confirms it
Agreed @Doc, but that's why the conjecture of a route through EMA. Could they be slightly porous to their french friends?
Consilium went on furlough about a week after they signed the contract with $NG due to the COVID situation.
I won't waste any more space on Traumakine here , but Hew , yes the WHO would not disclose any data to Faron , but the WHO report conclusions were based solely on subcutaneous delivery ( of which there were I believe over 5000 doses given ) .
It would be nice to get a tweet from synairgen in regards to what France have said, that's if its us
Try saying it with a Clouseau accent sounds passable Gallic.
But I think they would rather rub garlic in their eyes than save France with a very British product. Can’t see it.
Thinking sideways for a bit.
Could it be possible that an early readout / data from our Home Trial has been released to relevant authorities (EMA, perhaps) and France have jumped the gun somewhat..... maybe?
The French can be impulsive ....
Aha! Thanks PMJH for answering the May Day call! Very interesting indeed.
https://twitter.com/lolmcshizz/status/1365016170634612740?s=20
Just for the record , Farons drug did not fail with the WHO , it was never used . What was used was Mercks subcutaneous injection of Interferon Beta1a . Faron never got a look in .
The upshot ( excuse the pun) is that subcutaneous IFN Beta1a was written off as a possible contender .
Intravenous delivery ( Faron ) - is now being trialed in REMAP-CAP ( with no steroid mixing as that is the drugs achilles heel ) . It never got much of a look in on REMAP until recently , as they were giving every patient steroids as standard care - hence voiding the patient as a Traumakine candidate .
But it is getting its own trial in the USA now , actually being compared directly against steroids , and in reverse of previous care , will be administered FIRST , before steroids .
Not as universally useable as SNG001 , but it still may play a valid part in the fight against Covid , and particularly ARDS , when the lungs get too full of fluid for a nebuliser to be effective .
I think I remember a French lady scientist at the beginning of the pandemic working on neubulised Beta interferon 1b
Farons Traumakine is only on REMAP-CAP in Europe ( some french hospitals , but mostly UK , and so far not widely taken up due to steroid use )
USA Hibiscus trial yet to start for Faron , so don't think the French connection is Traumakine .
Anybody know much about this trial - in France using nebulised Interferon Beta 1b
Do you think this is what they are talking about ?
Not SNG - but either way - nebulised interferon
https://clinicaltrials.gov/ct2/show/NCT04356495?term=interferon&recrs=a&cond=Covid19&cntry=FR&draw=2&rank=5
Cannot believe the French PM would hail our treatment especially after the vaccine debacle and Brexit .
There is also a trial going on in the Amiens Hospital
And it’s not the French prime minister anyway ,
It’s the French HEALTH minister
I've had a look at the EU clinical trial register and can't see any trials for interferon in France. So I suspect it's SNG001 he's referring to.
This could be significant if it is us, the French health minister isnt going to risk losing face by discussing something which isnt showing real potential.
@sollod good spot that.
Could well be?
The reference to interferon for EPIC trial is ...... "Benefit of plasma exchanges in patients presenting anti-autoantibodiesType 1 interferon with severe COVID-19 -"
You sure pmjh. Looks like plasma trial. The translation...
(1) 3 exchange sessions of 1.5 times the plasma volume per 4% albumin on D1, D3, D5 in addition to the treatmentstandard including in particular dexamethasone.
(2) Standard treatment, including Dexamethasone